Benzinga | Oct 12, 2021 08:08AM EDT

BTIG Maintains Buy on Sarepta Therapeutics, Raises Price Target to $125

BTIG analyst Yun Zhong maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Buy and raises the price target from $110 to $125.